Security record · archived quarter
VRNA
Verona Pharma plc · Healthcare · Biotechnology
11Tracked holders
+3Δ holders
8.58MShares held
$398.41MReported value
+3New positions
−0Exits
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.03M | +61.0% | $140.49M | 0.0% | ▲ Add | 3 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 1.83M | +37.3% | $85.15M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.35M | +14.8% | $62.82M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Duquesne Family Office ✦ | 887.58K | +29.4% | $41.22M | 1.2% | ▲ Add | 2 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 711.01K | New | $33.02M | 0.1% | New | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 338.43K | New | $15.72M | 0.0% | New | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 171.45K | +7.2% | $7.96M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 152.10K | +117.5% | $7.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 62.74K | +1.1% | $2.91M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Marshall Wace ✦ | 28.62K | +123.4% | $1.33M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 11 | Renaissance Technologies ✦ | 15.50K | New | $719,820 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $33.02M | 0.1% |
| Adage Capital Partners | $15.72M | 0.0% |
| Renaissance Technologies | $719,820 | 0.0% |
Exited
| No tracked exits this quarter. |
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API